Approval · Notice of Compliance 37620 · 2026
YESINTEK: Notice of Compliance 37620
Issued May 21, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37620
- Date
- May 21, 2026
- Company
- Biocon Biologics Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative – Manufacturer name change
- Canadian reference product
- STELARA, STELARA I.V
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| YESINTEK | 02562081 | Marketed |
| YESINTEK | 02562103 | Marketed |
| YESINTEK | 02566478 | Approved |
| YESINTEK I.V. | 02562111 | Marketed |
Medicinal ingredients
- USTEKINUMAB 45 MG per 0.5ML
- USTEKINUMAB 90 MG per ML
- USTEKINUMAB 45 MG per 0.05ML
- USTEKINUMAB 130 MG per 26ML